By Dhirendra Tripathi
Investing.com – Shares of Emergent Biosolutions (NYSE:) and Johnson & Johnson (NYSE:) fell Thursday, after a report that regulators had delayed authorization to a plant making Covid-19 vaccines after a mix-up was found.
The plant, located in Baltimore, belongs to Emergent, a subcontractor of J&J, according to the report in The New York Times. Emergent shares fell 10% on concerns over issues related to quality control at the plant. J&J shares fell 1%.
The mix-up has delayed future shipments of J&J doses in the U.S. while the Food and Drug Administration investigates.
Further shipments of the J&J vaccine — expected to total 24 million doses in the next month — were supposed to come from the plant, the NYT said. J&J’s single dose shot has been credited for the speedy rollout of vaccination the U.S. and the falling cases. Pfizer (NYSE:) and Moderna (NASDAQ:), the others making Covid shots in the U.S., have two-dose vaccines.
The plant makes Covid-19 vaccines for AstraZeneca (NASDAQ:), too. The British-Swedish company’s vaccine is yet to be authorized for use in the U.S.
The federal government last year enlisted the plant to produce vaccines from J&J and AstraZeneca. The two vaccines use the same technology employing a harmless version of a virus — known as a vector. But J&J’s and AstraZeneca’s vectors are not interchangeable.
In late February, one or more workers somehow confused the two during the production process, raising questions about training and supervision, NYT said.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.